Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study

Aims SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D). Methods This multicentre, prospective, observational study enrolled adults with T2D with ≥ 1 documented HbA 1c value ≤ 12 weeks before semaglutide initiation. Primary endpoint was change in HbA 1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA 1c < 8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint. Results Overall, 214 patients initiated semaglutide (baseline HbA 1c 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA 1c reduced by −0.8 [95% CI − 1.01;−0.68] %-points (−9 [−11;−7] mmol/mol), BW by −5.0 kg [−5.73;−4.24] and WC by −4.8 cm [−5.75;−3.79] (all p < 0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA 1c < 8.0%, <7.5% and < 7.0%. No new safety signals were identified. Conclusions Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.